All forward-looking statements and cautionary statements included in this document are made as of the date hereof based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement or cautionary statement.
Health Discovery Corporation (OTCBB: HDVY), a molecular diagnostics company that uses patent protected advanced mathematical techniques for personalized medicine, reports on second week traction of its game-changing iPhone application, MelApp, from well-sourced iPhone app trackers. Tracking data from July 6 to July 18, 2011, show that MelApp has successfully achieved the status of ranking among the top 100 highest grossing apps in 38 individual countries in the Healthcare and Fitness category including such significant markets as the United States, Australia, Canada, Argentina, Brazil, Hong Kong, Russia, New Zealand, Japan, Singapore, Norway, Denmark and several European countries. Health Discovery Corporation (HDC) is particularly pleased to see early sales rankings of MelApp as the number one selling Healthcare and Fitness app in the Netherlands and Panama and among the top 30 in New Zealand and Australia, which have some of the highest rates of skin cancer in the world. “We are extremely pleased to achieve such high grossing ranks globally, especially since MelApp has only been on the market a couple of weeks,” notes Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. “We are also excited that we have received interest from academic as well as private practice physicians both in the US and internationally inquiring to be a part of our HDC physician referral network." Physicians who diagnose and treat melanoma can become a subscribing member of HDC’s physician referral network by contacting firstname.lastname@example.org. About MelApp & Health Discovery Corporation MelApp uses highly sophisticated patent protected mathematical algorithms and image based pattern recognition technology to analyze the uploaded image. MelApp was validated using an image database licensed from Johns Hopkins University Medical Center and uses the iPhone camera feature to deliver a risk analysis of user’s photographed skin lesions within seconds. The app can use the iPhone GPS to refer users to physicians specializing in the diagnosis and treatment of melanoma for proper medical follow-up. MelApp by Health Discovery Corporation was launched at a special limited time introductory price of $1.99 and is available in the iTunes App Store. For more complete details, visit http://www.melapp.net, http://www.facebook.com/MelApp or http://twitter.com/#!/SafeHealthApps. Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see www.healthdiscoverycorp.com. Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements in relation to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics, computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop and commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.